Organon & Co. (NYSE:OGN) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. trimmed its position in shares of Organon & Co. (NYSE:OGNGet Rating) by 11.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,414 shares of the company’s stock after selling 3,526 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Organon & Co. were worth $794,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in OGN. Twin Tree Management LP acquired a new stake in shares of Organon & Co. in the third quarter valued at about $76,000. Barclays PLC lifted its stake in Organon & Co. by 20.7% in the 3rd quarter. Barclays PLC now owns 170,870 shares of the company’s stock worth $3,997,000 after purchasing an additional 29,261 shares in the last quarter. Douglas Lane & Associates LLC lifted its stake in Organon & Co. by 102.6% in the 4th quarter. Douglas Lane & Associates LLC now owns 467,325 shares of the company’s stock worth $13,052,000 after purchasing an additional 236,693 shares in the last quarter. Jump Financial LLC boosted its holdings in shares of Organon & Co. by 42.2% during the 3rd quarter. Jump Financial LLC now owns 19,203 shares of the company’s stock worth $449,000 after purchasing an additional 5,701 shares during the last quarter. Finally, Kendall Capital Management grew its position in shares of Organon & Co. by 11.0% in the fourth quarter. Kendall Capital Management now owns 18,522 shares of the company’s stock valued at $517,000 after purchasing an additional 1,840 shares in the last quarter. 75.74% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Price Performance

NYSE:OGN opened at $20.43 on Monday. The company’s 50-day moving average is $22.72 and its two-hundred day moving average is $25.72. Organon & Co. has a 1-year low of $20.12 and a 1-year high of $39.09. The firm has a market capitalization of $5.21 billion, a price-to-earnings ratio of 7.00, a PEG ratio of 0.88 and a beta of 0.77.

Organon & Co. (NYSE:OGNGet Rating) last released its quarterly earnings data on Thursday, May 4th. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.10). The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative return on equity of 119.00%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.65 earnings per share. As a group, equities analysts anticipate that Organon & Co. will post 4.22 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Monday, May 15th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.48%. The ex-dividend date of this dividend is Friday, May 12th. Organon & Co.’s payout ratio is 38.36%.

Analyst Upgrades and Downgrades

Separately, Raymond James started coverage on Organon & Co. in a research note on Wednesday, March 15th. They set an “outperform” rating and a $33.00 price objective on the stock.

Organon & Co. Company Profile

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

Featured Articles

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNGet Rating).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.